Clinical Trial Update: Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab plus pemetrexed in elderly patients with non-squamous non-small cell lung cancer and PD-L1 < 50%.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: National Hospital Organization Nagoya Medical Center | Conditions: Non-squamous Non-small-cell Lung Cancer, Cancer, Lung | Phase 2 | Status: UNKNOWN